Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

144 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Liquid-Biopsy-Based Identification of EGFR T790M Mutation-Mediated Resistance to Afatinib Treatment in Patients with Advanced EGFR Mutation-Positive NSCLC, and Subsequent Response to Osimertinib.
Hochmair MJ, Buder A, Schwab S, Burghuber OC, Prosch H, Hilbe W, Cseh A, Fritz R, Filipits M. Hochmair MJ, et al. Among authors: cseh a. Target Oncol. 2019 Feb;14(1):75-83. doi: 10.1007/s11523-018-0612-z. Target Oncol. 2019. PMID: 30539501 Free PMC article. Clinical Trial.
Activity of Afatinib in Heavily Pretreated Patients With ERBB2 Mutation-Positive Advanced NSCLC: Findings From a Global Named Patient Use Program.
Peters S, Curioni-Fontecedro A, Nechushtan H, Shih JY, Liao WY, Gautschi O, Spataro V, Unk M, Yang JC, Lorence RM, Carrière P, Cseh A, Chang GC. Peters S, et al. Among authors: cseh a. J Thorac Oncol. 2018 Dec;13(12):1897-1905. doi: 10.1016/j.jtho.2018.07.093. Epub 2018 Aug 7. J Thorac Oncol. 2018. PMID: 30096481 Free article.
Afatinib in EGFR TKI-naïve patients with locally advanced or metastatic EGFR mutation-positive non-small cell lung cancer: Interim analysis of a Phase 3b study.
de Marinis F, Laktionov KK, Poltoratskiy A, Egorova I, Hochmair M, Passaro A, Migliorino MR, Metro G, Gottfried M, Tsoi D, Ostoros G, Rizzato S, Mukhametshina GZ, Schumacher M, Novello S, Dziadziuszko R, Tang W, Clementi L, Cseh A, Kowalski D. de Marinis F, et al. Among authors: cseh a. Lung Cancer. 2021 Feb;152:127-134. doi: 10.1016/j.lungcan.2020.12.011. Epub 2020 Dec 17. Lung Cancer. 2021. PMID: 33387727 Free article. Clinical Trial.
Experience from Asian centers in a named-patient-use program for afatinib in patients with advanced non-small-cell lung cancer who had progressed following prior therapies, including patients with uncommon EGFR mutations.
Chang GC, Lam DC, Tsai CM, Chen YM, Shih JY, Aggarwal S, Wang S, Kim SW, Kim YC, Wahid I, Li R, Lim DW, Sriuranpong V, Chan RT, Lorence RM, Carriere P, Raabe C, Cseh A, Park K. Chang GC, et al. Among authors: cseh a. Int J Clin Oncol. 2021 May;26(5):841-850. doi: 10.1007/s10147-021-01869-0. Epub 2021 Mar 30. Int J Clin Oncol. 2021. PMID: 33783657 Free PMC article.
A Phase IIIb Open-Label, Single-Arm Study of Afatinib in EGFR TKI-Naïve Patients with EGFRm+ NSCLC: Final Analysis, with a Focus on Patients Enrolled at Sites in China.
Tu HY, Feng J, Shi M, Zhao J, Wang Y, Chang J, Wang J, Cheng Y, Zhu J, Tan EH, Li K, Zhang Y, Lee V, Yang CT, Su WC, Lam DC, Srinivasa BJ, Rajappa S, Ho CL, Lam KC, Hu Y, Bondarde SA, Liu X, Tian Y, Xue Z, Cseh A, Huang DC, Zhou C, Wu YL. Tu HY, et al. Among authors: cseh a. Target Oncol. 2022 Jan;17(1):1-13. doi: 10.1007/s11523-021-00859-6. Epub 2022 Jan 12. Target Oncol. 2022. PMID: 35020119 Free PMC article. Clinical Trial.
Association of ERBB Mutations With Clinical Outcomes of Afatinib- or Erlotinib-Treated Patients With Lung Squamous Cell Carcinoma: Secondary Analysis of the LUX-Lung 8 Randomized Clinical Trial.
Goss GD, Felip E, Cobo M, Lu S, Syrigos K, Lee KH, Göker E, Georgoulias V, Li W, Guclu S, Isla D, Min YJ, Morabito A, Ardizzoni A, Gadgeel SM, Fülöp A, Bühnemann C, Gibson N, Krämer N, Solca F, Cseh A, Ehrnrooth E, Soria JC. Goss GD, et al. Among authors: cseh a. JAMA Oncol. 2018 Sep 1;4(9):1189-1197. doi: 10.1001/jamaoncol.2018.0775. JAMA Oncol. 2018. PMID: 29902295 Free PMC article. Clinical Trial.
Second-line Afatinib or Chemotherapy Following Immunochemotherapy for the Treatment of Metastatic, Squamous Cell Carcinoma of the Lung: Real-world Effectiveness and Safety From a Multisite Retrospective Chart Review in the USA.
Kim ES, Kish JK, Cseh A, Moehring B, Tang W, Terlizzi E, Subramanian J. Kim ES, et al. Among authors: cseh a. Clin Lung Cancer. 2021 Jul;22(4):292-300.e1. doi: 10.1016/j.cllc.2021.02.006. Epub 2021 Feb 16. Clin Lung Cancer. 2021. PMID: 33745863 Free article.
144 results